Hyperlipidemia
MONDO:0021187Also known as: hyperlipidemia, hyperlipidemia (disease), hyperlipemia, hyperlipemias, lipemia, lipemias, lipidemia, lipidemias
400 clinical trials for this condition and its sub-types, 306 tagged with Hyperlipidemia itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Hyperlipidemia
-
Familial hyperlipidemia 8 trials · 130 incl. sub-types
10 sub-types
- Familial hypercholesterolemia 58 trials · 94 incl. sub-types Sub-types →
- Hyperlipidemia, familial combined, LPL related 22 trials
- Familial lipoprotein lipase deficiency 6 trials
- Hyperlipoproteinemia type 3 4 trials
- Hyperlipoproteinemia type V 2 trials
- Cholesterol-ester transfer protein deficiency 0 trials
- Familial apolipoprotein C-II deficiency 0 trials
- Hyperlipidemia due to hepatic triglyceride lipase deficiency 0 trials
- Hyperlipidemia, combined, 2 0 trials
- Hyperlipoproteinemia, type 1D 0 trials
-
Hyperalphalipoproteinemia 0 trials
2 sub-types
-
Laminopathy type Decaudain-Vigouroux 0 trials
Most studied deeper sub-types
-
Experimental drug targets stubborn cholesterol in rare disease
Disease control Stopped earlyThis study tested an experimental drug called ARO-ANG3 in 18 people with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. Participants received injections of the drug and were monitored for safety and cholesterol change…
Phase 2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug for cholesterol and fatty liver fails to advance
Disease control Stopped earlyThis early-stage trial tested a new drug called LY3885125 in people with high cholesterol (dyslipidemia) and non-alcoholic fatty liver disease (NAFLD). The main goal was to check safety and how the body processes the drug. The study was terminated, meaning it stopped early, so it…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC